Replies to post #671 on Bristol Myers Squibb (BMY)

[Johnny_C]

I thought it was a little high myself, but she seems to have ties to BMY and she certainly had a cutesy smile discussing this.

Who knows, when PFE purportedly started having interest the stock was in low 50's. It is 30% higher now and has had some very good news, and the whole sector PPS has picked up.

My Oct 70's are toast. All top B/D guys for both companies are most likely 24/7 preparing for the Q call anyway.

[Johnny_C]

Looks like PFE not waiting until 2018 to decide whether to sell consumer goods. Bidding in November 2017.

With tax reform and repatriating looking solid there could a big deal be imminent.

Top choice is still BMY for me. But AGN, Biogen and a host of others could also be targets.

They have said they want to buy sales now, as every analyst seems to think the pipeline is solid in 25 to 48 months with a dozen or so blockbusters.

BMY has cash, no debt, have shed other business verticals to focus on oncology. Plus Eliquis. Perfect fit.

The million dollar question is whether BMY wants to do a deal with PFE.

For all the flack PFE gets for being boring, the stock has been a stud for us as we loaded the boat in the 13's. When you are the biggest it is hard to move the needle, but PFE has made up for Lipitor loss and a large merge like BMY or the like will make them the biggest drug company there by far.